42.365
-0.525 (-1.22%)
-0.525 (-1.22%)
Upgrade to Real-Time
Regular Market
Low
25.17
High
56.40
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Halozyme Therapeutics Incorporated | HALO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.525 | -1.22% | 42.365 | 13:05:41 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 42.92 | 41.97 | 43.08 | 42.89 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 42.35 | 42.38 | 0.03 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,560 | 152,532 | $ 42.44 | $ 6,473,936 | - | 25.17 - 56.40 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:05:41 | 200 | $ 42.365 | USD |
Period:
Draw Mode:
Halozyme Therapeutics Incorporated Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 6.03B | 142.39M | 122.53M | $ 267.59M | $ 134.14M | 0.91 | 37.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | -156.37k | 7.90% |
Halozyme Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HALO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 39.9534 | 43.545 | 39.9534 | 42.14 | 796,810 | 2.41 | 6.04% |
| 1 Month | 45.43 | 46.62 | 39.9534 | 43.94 | 635,299 | -3.07 | -6.75% |
| 3 Months | 50.43 | 50.72 | 38.65 | 43.06 | 913,122 | -8.07 | -15.99% |
| 6 Months | 48.285 | 56.40 | 38.65 | 45.07 | 1,143,049 | -5.92 | -12.26% |
| 1 Year | 27.32 | 56.40 | 25.17 | 39.42 | 1,303,251 | 15.05 | 55.07% |
| 3 Years | 17.34 | 56.40 | 12.71 | 26.40 | 1,164,391 | 25.03 | 144.32% |
| 5 Years | 9.26 | 56.40 | 8.18 | 21.55 | 1,190,582 | 33.11 | 357.51% |
Halozyme Therapeutics Description
| Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
